03 Experimental Therapeutics Program

03实验治疗(ET)计划 摘要 实验治疗(ET)计划是UAB的主要转化/临床研究引擎 Ccc。ET计划的主要目标是开发新的治疗策略，为癌症提供 有更多机会治愈的患者，如果没有治愈，生存时间也会增加 免于疾病进展，改善和缓解癌症相关症状(改善 生活质量)。对这一总目标的追求涉及三个科学目标：(1)推动和落实 涉及基础科学家和临床教师的转化性临床试验和临床前研究，(2)促进 有助于癌症诊断/预后、治疗预测的生物标志物的发现和验证 应对和选择最有可能从治疗方式中受益的人群，以及(3)促进 开发可集成到临床前和转化性临床的新型成像技术 学习。这些科学目标已经通过积极的孢子资助(大脑、乳房、胰腺和 宫颈癌)和苏珊·G·科门的治愈承诺赠款。此外，还有一个 与南方研究(SR)在药物发现和开发方面的科学合作显著扩大 与哈德逊·阿尔法生物技术研究所合作进行高通量基因测序。这种药 通过第一阶段临床试验的正规化，ET计划的发现工作得到了加强 计划，以及阿拉巴马州药物发现联盟(ADDA)的实施。与以下公司紧密合作 已经建立了其他国家研究小组，包括转化性乳腺癌研究 财团(TBCRC)和国家合作团体通过NCI U10-NCTC牵头学术 合作地点赠款。回旋加速器的收购和实施增加了主要的临床前和 具有临床PET研究能力的项目。最近的关键招聘显著提高了临床 过去两年的试行和应计。ET项目在#年持续增长 会员资格、研究预算和治疗试验的应计费用。ET项目中的主要教员代表 13个系，4所学校，SR和HudsonAlpha，教职员工总数从2011年的62人增加到 2015年为69人。总体研究预算从2011年的每年10,994,390美元增加到 2015年11,222,026美元的年度直接成本(2,450,158美元来自国家癌症研究所[NCI]，3,473,522美元来自 其他同行评审，以及45.881.01亿美元的行业年度直接研究支持)。患者应计至 在过去四年的资助期内，共有1717名患者进行了治疗试验，其中32%的患者 研究人员发起的试验，28%用于试点/第一阶段研究，33%用于第二阶段试验。这个节目有426个 过去五年筹资期间的出版物，包括27%的方案间出版物和29%的方案内出版物 计划性的作者。

03 EXPERIMENTAL THERAPEUTICS (ET) PROGRAM ABSTRACT The Experimental Therapeutics (ET) Program is the major translational/clinical research engine of the UAB CCC. The main objective of the ET Program is to develop novel therapeutic strategies that will provide cancer patients with an enhanced opportunity for cure and, if not cured, with an improved survival time, increased freedom from disease progression, and an improvement and relief of cancer-associated symptoms (improved quality of life). The pursuit of this overall objective involves three scientific aims: (1) to promote and implement translational clinical trials and preclinical research involving basic scientists and clinical faculty, (2) to promote discovery and validation of biomarkers that can aid in cancer diagnosis/prognosis, prediction of therapeutic response and selection of populations most likely to benefit from treatment modalities, and (3) to promote development of novel imaging technology that can be integrated into pre-clinical and translational clinical studies. These scientific goals have been enhanced by active SPORE funding (Brain, Breast, Pancreas, and Cervical cancers) and The Susan G. Komen for the Cure Promise Grant. In addition, there has been a significant expansion in scientific collaborations with Southern Research (SR) for drug discovery and development and HudsonAlpha Institute for Biotechnology for high-throughput genetic sequencing. The drug discovery efforts of the ET Program have been enhanced by the formalization of the Phase I Clinical trials Program, and the implementation of the Alabama Drug Discovery Alliance (ADDA). Strong collaborations with other national research groups have been established including the Translational Breast Cancer Research Consortium (TBCRC) and the National Cooperative Groups through the NCI U10-NCTC Lead Academic Partnership Site grant. The acquisition and implementation of the cyclotron has added major pre-clinical and clinical PET research capabilities to the program. Recent key recruitments have significantly enhanced clinical trial implementation and accrual over the last two years. The ET program has continued to grow in membership, research budget, and accrual to therapeutic trials. Primary faculty in the ET Program represent 13 departments, 4 schools, SR and HudsonAlpha, with total membership increasing from 62 faculty in 2011 to 69 in 2015. The overall research budget has increased from $10,994,390 annual direct costs in 2011 to $11,222,026 annual direct costs in 2015 ($2,450,158 from the National Cancer Institute [NCI], $3,473,522 of other peer-reviewed, and $4,588,101 million in Industry annual direct research support). Patient accrual to therapeutic trials over the past four year funding period was 1,717 patients, including 32% accrual to investigator-initiated trials, 28% to pilot/phase I studies, and 33% to phase II trials. The program had 426 publications over the past five year funding period including 27% inter-programmatic and 29% intra- programmatic authorship.